New investor Greatbatch has led the round with a $5m commitment, with the remaining cash coming from existing stakeholders.

Aleva Neurotherapeutics, a Switzerland-based medical device company focused on brain implants, has raised $18m in a series C round led by medical device manufacturer Greatbatch.

BioMedPartners, BB Biotech Ventures, Banexi Ventures, Initiative Capital Romandie and a range of family offices including Kinled Holding and Forrestal Capital also contributed funds.

The money represents a first close for the round.

Greatbatch’s commitment follows a strategic development, supply and manufacturing agreement signed with Aleva in February 2016. As part of that partnership, Aleva…